Our Pipeline

Autoimmune diseases affect approximately 15 million people in the U.S., representing 4.6% of the population. Current therapies rely on broad immune suppression that alleviates symptoms but carries long-term toxicity and increased infection risk. Biologics with improved selectivity are available for severe disease, but they do not halt progression and fail in up to 40% of patients. Emerging approaches may not induce durable effects or be applicable to many autoimmune diseases, or may rely on unproven delivery technologies or cumbersome manufacturing approaches.

Advancing disease modifying therapies

We are building a pipeline of therapies designed to achieve disease-modification for patients with autoimmunity. Our thymus-targeted, bifunctional antibodies are designed to retrain the immune system to halt ongoing autoimmune attack while promoting the repair and restoration of healthy tissue. Our lead program, ZAG-101, is being developed for Type 1 diabetes, with additional programs advancing in autoimmune diseases of the gastrointestinal tract, skin, and nervous system.